Abstract
Effector cytotoxic T lymphocytes (CTLs) are induced from resting precursors (small lymphocytes) which do not express cytotoxic activity. The process of CTL activation, which occurs in 2–7 days following mitogen or antigen stimulation, thus involves a differentiation event and normally also involves proliferation. These events in CTL activation seem to be induced, at least in part, by soluble, antigen-nonspecific mediators which reach the CTL precursor as a consequence of cell–cell interactions during the immune response. The initial evidence for this was the finding that in addition to CTL precursors, la-positive macrophage-like accessory cells1–4, and helper T cells5–10 are required for the induction of CTL activity in vitro. Furthermore, the requirement for accessory cells can be replaced with factors present in concanavalin A (Con A)-induced cultures of spleen cells11. There is evidence that T-cell products such as interleukin-2 (IL-2, formerly T-cell growth factor)11–15 as well as accessory cell products, such as inter-leukin-1 (IL-1, formerly lymphocyte activating factor)4,15, are involved in T-cell activation, although the precise roles of these factors in CTL activation are poorly understood. Here we provide evidence for a factor, different from IL-1 and IL-2, which is present in supernatants of Con A-activated mouse spleen cells and is required for the differentiation of CTL precursors into active CTLs.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Wagner, H., Feldman, M., Boyle, W. & Schrader, J. W. J. exp. Med. 136, 331–340 (1972).
Koren, H. S. & Hodes, R. J. Eur. J. Immun. 7, 394 (1977).
Taniyama, T. & Holden, H. T. J. Immun. 123, 43–49 (1979).
Farrar, W. L., Mizel, S. B. & Farrar, J. J. J. Immun. 124, 1371–1377 (1980).
Cantor, H. & Boyse, E. A. J. exp. Med. 141, 1390–1399 (1975).
Von Boehmer, H. & Haas, W. Immun. Rev. 54, 27–56 (1981).
Wagner, H. et al. Immun. Rev. 51, 215 (1980).
Cooley, M. A. & Schmitt-Verhulst, A.-M. J. Immun. 123, 2328–2336 (1979).
Glasebrook, A. & Fitch, F. J. exp. Med. 151, 876–895 (1980).
Finberg, R., Green, M., Benacerraf, B. & Burakoff, S. J. J. Immun. 123, 1205–1209 (1979).
Farrar, W. L., Johnson, H. M. & Farrar, J. J. J. Immun. 126, 1120–1125 (1981).
Morgan, D. A., Ruscetti, F. W. & Gallo, R. C. Science 193, 1007–1008 (1976).
Gillis, S. & Smith, K. A. Nature 268, 154–156 (1977).
Schreier, M. H., Iscove, N. N., Tees, R., Aarden, L. & Von Boehmer, H. J. Immun. Rev. 51, 315–336 (1980).
Larsson, E.-L., Iscove, N. N. & Coutinho, A. Nature 283, 664–666 (1980).
Bevan, M. J. & Cohn, M. J. Immun. 114, 559–565 (1975).
Habu, S. & Raff, M. C. Eur. J. Immun. 7, 451–457 (1977).
Möller, G., Sjöberg, O. & Andersson, J. Eur. J. Immun. 2, 586 (1972).
Gillis, S. & Smith, K.A. J. Immun. 120, 2027–2032 (1978).
Harwell, L., Skidmore, B., Marrack, P. & Kappler, J. J. exp. Med. 152, 893–904 (1980).
Kappler, J. W., Skidmore, B., White, J. & Marrack, P. J. exp. Med. 153, 1198–1214 (1981).
Cantor, H. & Boyse, E. A. J. exp. Med. 141, 1376–1389 (1975).
Mochizuki, D., Watson, J. & Gillis, S. J. Immun. 125, 2579–2583 (1980).
Mizel, S. B. J. Immun. 122, 2167–2172 (1979).
Baker, P. E., Gillis, S. & Smith, K. A. J. exp. Med. 149, 273 (1979).
Parker, D. C. Immun. Rev. 52, 115 (1980).
Swain, S. L., Dennert, G., Warner, J. F. & Dutton, R. W. Proc. natn. Acad. Sci. U.S.A. 78, 2517–2521 (1981).
Parker, D. C. J. Immun. (submitted).
Liebson, J., Marrack, P. & Kappler, J. J. exp. Med. 154, 1681 (1981).
Wysocki, L. J. & Sato, V. L. Proc. natn. Acad. Sci. U.S.A. 75, 2844 (1978).
Raulet, D. H., Gottlieb, P. D. & Bevan, M. J. J. Immun. 125, 1136–1143 (1980).
Julius, M. H., Simpson, E. & Herzenberg, L. A. Eur. J. Immun. 3, 645–649 (1973).
Cerottini, J. C., Engers, H. D., MacDonald, H. R. & Brunner, K. T. J. exp. Med. 140, 703 (1974).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Raulet, D., Bevan, M. A differentiation factor required for the expression of cytotoxic T-cell function. Nature 296, 754–757 (1982). https://doi.org/10.1038/296754a0
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/296754a0
This article is cited by
-
Autologous tumour-specific cytotoxic T-cell clone established from tumour-infiltrating lymphocytes (TIL) of malignant ascites in the absence of recombinant interleukin 2(rIL2): Activation by autologous tumour cell alone
Biotherapy (1993)
-
Regulation of cytolytic T-lymphocyte generation by B-cell stimulatory factor
Nature (1987)
-
Signal requirements in the step-wise functional maturation of cytotoxic T lymphocytes
Nature (1987)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.